Member Info for Laura2022

Actually it's the opposite to a vice grip

There is very few shares to buy and I think there is a large move coming

Regular now

Moving now

This has fallen 4p to 0.2p I'm just 2mths

There will be an interesting few weeks

Remember MEN Tony ?

It went 500% in April in similar circumstances

But can sell everything at nearly 0.18p

Yes Jony

I would like to add 500k more but cannot

Which is why I think there a chance a Chinese buyer etc may swoop before 16th August and de rail the BODs crooked plan

Thanks trench

Just 4mths ago they said this:

Directors are pulling a fast one !!

6.4Moz of gold however with a market capitalisation that, in the Board's view, does not yet reflect this and which serves to highlight the significant upside potential for investors

We were delighted to have signed the EPC contract with Power China. This was completed on a fixed lump sum basis, ensuring that we have clarity on costs and allowing us to turn our attention to expanding the mine life of Tulkubash beyond six years by evaluating other mining areas.

"Chaarat is now at a crucial stage of its development as we look to unlock the significant value of Tulkubash, and, in the longer-term, Kyzyltash. We are a mining company with a global resource inventory of 6.4Moz of gold however with a market capitalisation that, in the Board's view, does not yet reflect this and which serves to highlight the significant upside potential for investors once we secure funding to enable us to eventually move into our first phase of production at Tulkubash."

Not much to buy at 0.2p

Also anoth3r mining company could swoop as Cgh asset huge

Diseases & Statistics:

Methods for Analyzing Composite Patient Outcomes Code

ENDPOINTS

RCT

ORDINAL

REGRESSION

2024

BAYES

DESIGN

MEASUREMENT

POSTERIOR

PRINCIPLES

RESPONDER-ANALYSIS

SAMPLE-SIZE

SURVIVAL-ANALYSIS

In this talk I’ll explain why statistical power is maximized by analyzing the rawest form of clinical trial outcome data, as opposed to analyzing patients at a single time point or reducing rich longitudinal data to time-to-event outcomes. Analyzing all the data longitudinally also provides a formal way to handle missing or partially missing data. 

To secure the vote

Corporate Update

 

Post receiving the US$0.25 million Initial Advance from the issue of Additional Notes, the Company's current cash balance is c. US$0.4 million. This provides the Company with sufficient working capital for its ongoing operational and corporate requirements at least until the Cancellation on 16  August 2024. Assuming the Resolutions are approved, further drawdowns on the US$5 million facility are expected to be made available to the Company shortly following Cancellation.

 

Further to the Company's announcement on 16 July 2024, Cancellation is to be proposed, alongside several other resolutions related to the Recapitalisation, at the General Meeting to be held on the 8 August 2024 and will take effect, if approved, from 7.00am on 16 August 2024. As per the Circular to shareholders dated 16 July 2024, the Directors are unanimously recommending that Shareholders vote in favour of the resolutions being proposed at the General Meeting. Should the Resolutions not be approved at the General Meeting then, based on the liabilities of the Company, the Company will be forced into immediate insolvency proceedings, in which case Shareholders will most likely realise zero value from their investment into the Company. Shareholders should note that the insolvency proceedings would also trigger an immediate suspension from trading of the Company's Shares.

Thanks Ralph

Recruitment of a Head of Mathematical Modelling Service Line to accelerate conversion of the pipeline and drive operational excellence.

· Further investment in Business Development and Marketing to build and strengthen the pipeline, expand into new therapeutic areas, develop its data science offering and launch its biostatistics offering.

· Build a biostatistics capability, including team expansion, development of processes, acquisition of necessary tools and exploration of strategic options.

Yes, as explained in every RNS thus far so no crystal balls needed

Gordon

Hello

Check out PYC, it's £1.2mln and fully funded A.I medical stock amd it's got similar A.I software that just been bought for £40mln on IUG yesterday

Really awful news for holders

Hope it gets sorted for investors

Amazing summary thanks KingH

Apparently only 2 market makers have access to trading platforms across LSE stock exchange

I'm struggling to get a qoute also to buy

Thanks KingH

Based on yesterday A.I news then PYC with a core business AND a dosing A.I app then 3p-5p minimum